Health Blueprint

Back to Longevity News

News summary

MetaVia’s DA-1726 shows weight and liver fat reductions

Source: Longevity Technology • Published: 11 Nov 2026, 12:36

Summarized by Masters of Longevity from Longevity Technology.

Company data showed DA-1726 lowered body weight and liver fat measures.

MetaVia’s DA-1726 shows weight and liver fat reductions
Key Takeaways
  • DA-1726 is a once-weekly dual GLP-1 and glucagon analogue.
  • Preclinical studies showed DA-1726 concentrated in adipose tissue.
  • A 48-week Phase 2 study for MetALD and ALD is planned.
Read the full article at Longevity Technology ↗

Continue exploring

Recommended MoL Picks

MoL PickThe Next Obesity-Drug Race Is About What Weight You LoseRegeneron’s myostatin and activin A antibodies point to a sharper question for the GLP-1 era: not whether people can lose more weight, but whether medicine can preserve the tissue that makes weight loss healthier.MoL PickSemaglutide Extended Lifespan in Mice. What Would Make It a Human Longevity Drug?A new animal study sharpens an important question: when do benefits in a particular disease become evidence for a longer, healthier life?MoL PickApoB: The cholesterol signal LDL can missIn longevity medicine, the useful biomarkers are not always the exotic ones. ApoB is a relatively simple blood test that can sharpen cardiovascular prevention when LDL-C looks reassuring but particle burden remains high.